An interventional study of Placebo and Kava and Kratom Herbal Supplement in Anxiety, Physiological Stress and Stress, sponsored by Botanic Tonics, LLC. Recruiting at 1 site in Canada. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Botanic Tonics, LLC · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is being conducted to assess the effects of the Feel Free® Classic Tonic on stress in healthy adults. The goal is to see whether the tonic can help reduce self-perceived and physiological stress and provide information on how its ingredients are processed in the body.
This is a randomized, double-blind, parallel, 3-arm, placebo-controlled study to assess the effects of two dose levels of the Feel Free® Classic Tonic on stress in healthy adults. The primary goal is to evaluate how the tonic affects self-reported and physiological measures of stress and anxiety. A pharmacokinetic sub-study will assess how the tonic's components are absorbed and processed. The tonic contains kava and kratom, botanicals traditionally used for relaxation and mood support, and early data suggest it is generally well tolerated.
7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.
This study's planned enrollment of 165 is above the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.
Browse Anxiety Disorders studies →Botanic Tonics, LLC is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Sub-Study participants only:
Exclusion Criteria:
Currently consumes more than two (2) standard alcoholic beverages per day on average for 4 weeks.
Note: A standard alcoholic beverage is defined as 12 ounces of beer, 5 ounces of wine, or 1.5 ounces of liquor.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No Active Product per bottle
Other: Placebo
Active Product of 380 mg Kava root extract and 1480 mg of dried Kratom Leaf powder per bottle
Other: Kava and Kratom Herbal Supplement
Active Product of 190 mg Kava root extract and 740 mg of dried Kratom Leaf powder per bottle
Other: Kava and Kratom Herbal Supplement
Placebo
Feel Free Classic Tonic Dose 1 (TP1)
Feel Free Classic Tonic Dose 2 (TP2 - Half Strength)
Change in Perceived Stress Scale-10 (PSS-10) Score
Change in PSS-10 score from baseline to Day 29 to assess the effect of the test product on self-perceived stress. Items are scored on a 5-point Likert scale ranging from 0 ('Never') to 4 ('Very Often'). Higher scores indicate higher perceived stress levels.
Time frame: Baseline (Day 1) to Day 29
Change in State-Trait Anxiety Inventory - State (STAI-S) - Single Dose
Change in STAI-S score from pre-dose to post-dose (pre-Trier Social Stress Test - Arithmetic \[pre-TSST-A\]) on Day 1 after a single dose. The scale assesses how participants feel "right-now". It measures subjective and temporary fluctuations in feelings associated with anxiety. Items (e.g., "I worry too much over something that really doesn't matter", "I am content") are rated on a 4-point scale, such as from "Almost Never" to "Almost Always". Higher score to be a higher anxiety.
Time frame: Day 1 pre-dose to Day 1 post-dose (pre-TSST-A)
Change in State-Trait Anxiety Inventory - State (STAI-S) During TSST-A (Trier Social Stress Test - Arithmetic) - Single Dose
Change in STAI-S score from pre-TSST-A to post-TSST-A at 0, 15, 25, and 55 minutes on Day 1. The scale assesses how participants feel "right-now". It measures subjective and temporary fluctuations in feelings associated with anxiety. Items (e.g., "I worry too much over something that really doesn't matter", "I am content") are rated on a 4-point scale, such as from "Almost Never" to "Almost Always". Higher score to be a worse outcome.
Time frame: Day 1 assessments at pre-TSST-A, and post-TSST-A at 0, 15, 25, 55 minutes
Change in State-Trait Anxiety Inventory - State (STAI-S) - Multiple-Day Dosing
Change in STAI-S score from pre-dose to post-dose (pre-Trier Social Stress Test - Arithmetic \[pre-TSST-A\]) on Day 29 after a single dose. The scale assesses how participants feel "right-now". It measures subjective and temporary fluctuations in feelings associated with anxiety. Items (e.g., "I worry too much over something that really doesn't matter", "I am content") are rated on a 4-point scale, such as from "Almost Never" to "Almost Always". Higher score to be a worse outcome.
Time frame: Day 29 pre-dose to Day 29 pre-TSST-A
Change in State-Trait Anxiety Inventory - State (STAI-S) During TSST-A (Trier Social Stress Test - Arithmetic) - Multiple-Day Dosing
Change in STAI-S score from pre-TSST-A to post-TSST-A at 0, 15, 25, and 55 minutes on Day 29. The scale assesses how participants feel "right-now". It measures subjective and temporary fluctuations in feelings associated with anxiety. Items (e.g., "I worry too much over something that really doesn't matter", "I am content") are rated on a 4-point scale, such as from "Almost Never" to "Almost Always". Higher score to be a worse outcome.
Time frame: Day 29 measurements at pre-TSST-A, and post-TSST-A at 0, 15, 25 and 55 minutes.
Change in State-Trait Anxiety Inventory - Trait (STAI-T)
Change in STAI-T score from pre-dose Day 1 to pre-dose Day 29. The scale assesses how respondents feel "generally". It measures relatively stable individual differences in anxiety proneness. Items (e.g., "I worry too much over something that really doesn't matter", "I am content") are rated on a 4-point scale, such as from "Almost Never" to "Almost Always". Higher score to be a higher anxiety.
Time frame: Day 1 to Day 29
Physiological Stress Markers (Cortisol) - Single Dose
Change in salivary cortisol (µg/dL) from pre-dose to post-dose (pre-Trier Social Stress Test - Arithmetic \[pre-TSST-A\]) on Day 1.
Time frame: Day 1
Physiological Stress Markers (Alpha-Amylase) - Single Dose
Change in alpha-amylase (U/mL) from pre-dose to post-dose (pre-Trier Social Stress Test - Arithmetic \[pre-TSST-A\]) on Day 1
Time frame: Day 1
Physiological Stress Markers (Cortisol) During Trier Social Stress Test - Arithmetic (TSST-A) - Single Dose
Change in salivary cortisol (µg/dL) from pre-TSST-A to 10, 20, 30, and 60 minutes post-TSST-A
Time frame: Day 1
Physiological Stress Markers (Alpha-Amylase) During Trier Social Stress Test - Arithmetic (TSST-A) - Single Dose
Change in salivary alpha-amylase (U/mL) from pre-TSST-A to 10, 20, 30, and 60 minutes post-TSST-A
Time frame: Day 1
Physiological Stress Markers (Heart Rate) During Trier Social Stress Test - Arithmetic (TSST-A) - Single Dose
Change in heart rate (bpm) from pre-TSST-A to 60 minutes post-TSST-A.
Time frame: Day 1
Physiological Stress Markers (Cortisol) - Multiple-Day Dose
Change in salivary cortisol (µg/dL) from pre-dose to post-dose (pre-Trier Social Stress Test - Arithmetic \[pre-TSST-A\]) on Day 29.
Time frame: Day 29
Physiological Stress Markers (Alpha-Amylase) - Multiple-Day Dose
Change in salivary alpha-amylase (U/mL) from pre-dose to post-dose (pre-Trier Social Stress Test - Arithmetic \[pre-TSST-A\]) on Day 29.
Time frame: Day 29
Physiological Stress Markers (Cortisol) During Trier Social Stress Test - Arithmetic (TSST-A) - Multiple-Day Dosing
Change in salivary cortisol (µg/dL) from pre-TSST-A to 10, 20, 30, and 60 minutes post-TSST-A.
Time frame: Day 29
Physiological Stress Markers (Alpha-Amylase) During Trier Social Stress Test - Arithmetic (TSST-A) - Multiple-Day Dosing
Change in salivary alpha-amylase (U/mL) from pre-TSST-A to 10, 20, 30, and 60 minutes post-TSST-A
Time frame: Day 29
Physiological Stress Markers (Heart Rate) During Trier Social Stress Test - Arithmetic (TSST-A) - Multiple-Day Dosing
Change in heart rate (bpm) from pre-TSST-A to 60 minutes post-TSST-A.
Time frame: Day 29
Awakening Cortisol Response
Change in morning awakening salivary cortisol over 30 minutes from baseline to Day 29.
Time frame: Baseline Day 1 to Day 29
Awakening Alpha-Amylase Response
Change in morning awakening alpha-amylase over 30 minutes from baseline to Day 29
Time frame: Baseline Day 1 to Day 29
PK Profile of Mitragynine AUC0-8 (Single Dose)
Area under the plasma concentration (AUC) -time curve from 0 to 8 hours after a single dose.
Time frame: Day 1 (0-8 hours)
PK Profile of Mitragynine AUC8-24 (Single Dose)
Area under the plasma concentration (AUC)-time curve from 8 to 24 hours after a single dose.
Time frame: Day 1-Day 2 (8-24 hours)
PK Profile of Mitragynine AUC0-24 (Single Dose)
Area under the plasma concentration (AUC) -time curve from 0 to 24 hours after a single dose.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of Mitragynine AUC0-∞ (Single Dose)
Area under the plasma concentration (AUC) -time curve from 0 to infinity after a single dose.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of Mitragynine Cmax (Single Dose)
Maximum observed plasma concentration (Cmax) after a single dose from 0 to 24 hours.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of Mitragynine Tmax (Single Dose)
Time to reach maximum observed plasma concentration (Tmax) after a single dose from 0 to 24 hours.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of Mitragynine Half-Life (T½) (Single Dose)
Terminal elimination half-life after a single dose from 0 to 24 hours.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of Mitragynine Elimination Rate Constant (Kel) (Single Dose)
Terminal elimination rate constant after a single dose from 0 to 24 hours.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of 7-hydroxymitragynine AUC0-8 (Single Dose)
Area under the plasma concentration (AUC) -time curve from 0 to 8 hours after a single dose.
Time frame: Day 1 (0-8 hours)
PK Profile of 7-hydroxymitragynine AUC8-24 (Single Dose)
Area under the plasma concentration (AUC) -time curve from 8 to 24 hours after a single dose.
Time frame: Day 1-Day 2 (8-24 hours)
PK Profile of 7-hydroxymitragynine AUC0-24 (Single Dose)
Area under the plasma concentration (AUC) -time curve from 0 to 24 hours after a single dose.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of 7-hydroxymitragynine AUC0-∞ (Single Dose)
Area under the plasma concentration (AUC) -time curve from 0 to infinity after a single dose.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of 7-hydroxymitragynine Cmax (Single Dose)
Maximum observed plasma concentration (Cmax) after a single dose from 0 to 24 hours.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of 7-hydroxymitragynine Tmax (Single Dose)
Time to reach maximum observed plasma concentration (Tmax) after a single dose from 0 to 24 hours.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of 7-hydroxymitragynine Half-Life (T½) (Single Dose)
Terminal elimination half-life after a single dose from 0 to 24 hours.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of 7-hydroxymitragynine Elimination Rate Constant (Kel) (Single Dose)
Terminal elimination rate constant after a single dose from 0 to 24 hours.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of Kavain AUC0-8 (Single Dose)
Area under the plasma concentration (AUC) -time curve from 0 to 8 hours after a single dose.
Time frame: Day 1 (0-8 hours)
PK Profile of Kavain AUC8-24 (Single Dose)
Area under the plasma concentration (AUC) -time curve from 8 to 24 hours after a single dose.
Time frame: Day 1-Day 2 (8-24 hours)
PK Profile of Kavain AUC0-24 (Single Dose)
Area under the plasma concentration (AUC) -time curve from 0 to 24 hours after a single dose.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of Kavain AUC0-∞ (Single Dose)
Area under the plasma concentration (AUC) -time curve from 0 to infinity after a single dose.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of Kavain Cmax (Single Dose)
Maximum observed plasma concentration (Cmax) after a single dose from 0 to 24 hours.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of Kavain Tmax (Single Dose)
Time to reach maximum observed plasma concentration (Tmax) after a single dose from 0 to 24 hours.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of Kavain Half-Life (T½) (Single Dose)
Terminal elimination half-life after a single dose from 0 to 24 hours.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of Kavain Elimination Rate Constant (Kel) (Single Dose)
Terminal elimination rate constant after a single dose from 0 to 24 hours.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of Dihydrokavain AUC0-8 (Single Dose)
Area under the plasma concentration (AUC) - time curve from 0 to 8 hours after a single dose.
Time frame: Day 1 (0-8 hours)
PK Profile of Dihydrokavain AUC8-24 (Single Dose)
Area under the plasma concentration (AUC) - time curve from 8 to 24 hours after a single dose.
Time frame: Day 1-Day 2 (8-24 hours)
PK Profile of Dihydrokavain AUC0-24 (Single Dose)
Area under the plasma concentration (AUC) - time curve from 0 to 24 hours after a single dose.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of Dihydrokavain AUC0-∞ (Single Dose)
Area under the plasma concentration (AUC) - time curve from 0 to infinity after a single dose.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of Dihydrokavain Cmax (Single Dose)
Maximum observed plasma concentration (Cmax) after a single dose from 0 to 24 hours.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of Dihydrokavain Tmax (Single Dose)
Time to reach maximum observed plasma concentration (Tmax) after a single dose from 0 to 24 hours.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of Dihydrokavain Half-Life (T½) (Single Dose)
Terminal elimination half-life after a single dose from 0 to 24 hours.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile of Dihydrokavain Elimination Rate Constant (Kel) (Single Dose)
Terminal elimination rate constant after a single dose from 0 to 24 hours.
Time frame: Day 1-Day 2 (0-24 hours)
PK Profile Mitragynine AUC0-8, Steady State (Multiple-Day Dose)
Area under the plasma concentration (AUC)- time curve from 0 to 8 hours at steady state after multiple-day dosing.
Time frame: Day 29 (0-8 hours)
PK Profile Mitragynine AUC8-24, Steady State (Multiple-Day Dose)
Area under the plasma concentration (AUC)- time curve from 8 to 24 hours at steady state after multiple-day dosing.
Time frame: Day 29-30 (8-24 hours)
PK Profile Mitragynine AUC0-24, Steady State (Multiple-Day Dose)
Area under the plasma concentration (AUC)- time curve from 0 to 24 hours at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile Mitragynine AUC0-∞, Steady State (Multiple-Day Dose)
Area under the plasma concentration (AUC)- time curve from 0 to infinity at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile Mitragynine Cmax, Steady State (Multiple-Day Dose)
Maximum observed plasma concentration (Cmax) at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile Mitragynine Tmax, Steady State (Multiple-Day Dose)
Time to reach maximum observed plasma concentration (Tmax) at steady state.
Time frame: Day 29-30 (0-24 hours)
PK Profile Mitragynine Half-Life (T1/2) at Steady State (Multiple-Day Dose)
Terminal elimination half-life at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile Mitragynine Elimination Rate Constant (Kel) at Steady State (Multiple-Day Dose)
Terminal elimination rate constant at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile 7-hydroxymitragynine AUC0-8, Steady State (Multiple-Day Dose)
Area under the plasma concentration (AUC)- time curve from 0 to 8 hours at steady state after multiple-day dosing.
Time frame: Day 29 (0-8 hours)
PK Profile 7-hydroxymitragynine AUC8-24, Steady State (Multiple-Day Dose)
Area under the plasma concentration (AUC)- time curve from 8 to 24 hours at steady state after multiple-day dosing.
Time frame: Day 29-30 (8-24 hours)
PK Profile 7-hydroxymitragynine AUC0-24, Steady State (Multiple-Day Dose)
Area under the plasma concentration (AUC)- time curve from 0 to 24 hours at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile 7-hydroxymitragynine AUC0-∞, Steady State (Multiple-Day Dose)
Area under the plasma concentration (AUC)- time curve from 0 to infinity at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile 7-hydroxymitragynine Cmax, Steady State (Multiple-Day Dose)
Maximum observed plasma concentration (Cmax) at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile 7-hydroxymitragynine Tmax, Steady State (Multiple-Day Dose)
Time to reach maximum observed plasma concentration (Tmax) at steady state.
Time frame: Day 29-30 (0-24 hours)
PK Profile 7-hydroxymitragynine Half-Life (T1/2) at Steady State (Multiple-Day Dose)
Terminal elimination half-life at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile 7-hydroxymitragynine Elimination Rate Constant (Kel) at Steady State (Multiple-Day Dose)
Terminal elimination rate constant at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile Kavain AUC0-8, Steady State (Multiple-Day Dose)
Area under the plasma concentration (AUC)- time curve from 0 to 8 hours at steady state after multiple-day dosing.
Time frame: Day 29 (0-8 hours)
PK Profile Kavain AUC8-24, Steady State (Multiple-Day Dose)
Area under the plasma concentration (AUC)- time curve from 8 to 24 hours at steady state after multiple-day dosing.
Time frame: Day 29-30 (8-24 hours)
PK Profile Kavain AUC0-24, Steady State (Multiple-Day Dose)
Area under the plasma concentration (AUC)- time curve from 0 to 24 hours at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile Kavain AUC0-∞, Steady State (Multiple-Day Dose)
Area under the plasma concentration (AUC)- time curve from 0 to infinity at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile Kavain Cmax, Steady State (Multiple-Day Dose)
Maximum observed plasma concentration (Cmax) at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile Kavain Tmax, Steady State (Multiple-Day Dose)
Time to reach maximum observed plasma concentration (Tmax) at steady state.
Time frame: Day 29-30 (0-24 hours)
PK Profile Kavain Half-Life (T1/2) at Steady State (Multiple-Day Dose)
Terminal elimination half-life at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile Kavain Elimination Rate Constant (Kel) at Steady State (Multiple-Day Dose)
Terminal elimination rate constant at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile Dihydrokavain AUC0-8, Steady State (Multiple-Day Dose)
Area under the plasma concentration (AUC)- time curve from 0 to 8 hours at steady state after multiple-day dosing.
Time frame: Day 29 (0-8 hours)
PK Profile Dihydrokavain AUC8-24, Steady State (Multiple-Day Dose)
Area under the plasma concentration (AUC)- time curve from 8 to 24 hours at steady state after multiple-day dosing.
Time frame: Day 29-30 (8-24 hours)
PK Profile Dihydrokavain AUC0-24, Steady State (Multiple-Day Dose)
Area under the plasma concentration (AUC)- time curve from 0 to 24 hours at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile Dihydrokavain AUC0-∞, Steady State (Multiple-Day Dose)
Area under the plasma concentration (AUC)- time curve from 0 to infinity at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile Dihydrokavain Cmax, Steady State (Multiple-Day Dose)
Maximum observed plasma concentration (Cmax) at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile Dihydrokavain Tmax, Steady State (Multiple-Day Dose)
Time to reach maximum observed plasma concentration (Tmax) at steady state.
Time frame: Day 29-30 (0-24 hours)
PK Profile Dihydrokavain Half-Life (T1/2) at Steady State (Multiple-Day Dose)
Terminal elimination half-life at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
PK Profile Dihydrokavain Elimination Rate Constant (Kel) at Steady State (Multiple-Day Dose)
Terminal elimination rate constant at steady state after multiple-day dosing.
Time frame: Day 29-30 (0-24 hours)
Trough Plasma Concentrations Over Time
To measure trough plasma concentrations of kratom alkaloids and kavalactones during repeated twice-daily dosing, using pre-dose blood samples collected on alternate days over the first 14 days of study product use. This evaluates concentration buildup prior to steady-state attainment.
Time frame: Days 1-15 (pre-dose trough sampling)
Comparison of Single-Dose vs Steady-State Cmax
Difference between between single-dose maximum observed plasma concentration (Cmax) on Day 1 and and steady-state Cmax at Day 29 to evaluate systemic accumulation.
Time frame: Single dose: Day 1 and Day 2 (0-24 hours) Steady State: Day 29 and Day 30 (0-24 hours), Day 31 (48h), Day 36 (168h)
Comparison of Single-Dose vs Steady-State AUC0-8
Difference between single-dose area under the plasma concentration (AUC0-8) (Day 1) and steady-state AUC0-8 (Day 29) to assess accumulation over the first 8 hours.
Time frame: Single dose: Day 1 and Day 2 (0-24 hours) Steady State: Day 29 and Day 30 (0-24 hours), Day 31 (48h), Day 36 (168h)
Comparison of Single-Dose vs Steady-State AUC0-24
Difference between single-dose area under the plasma concentration (AUC0-24) (Day 1 and Day 2) and steady-state AUC0-24 (Day 29 and Day 30) to assess the 24-hour exposure accumulation.
Time frame: Single dose: Day 1 and Day 2 (0-24 hours) Steady State: Day 29 and Day 30 (0-24 hours), Day 31 (48h), Day 36 (168h)
Perception of Trier Social Stress Test - Arithmetic (TSST-A) Task
Perception of the task survey at completion of TSST-A on Days 1 and 29. This non-validated questionnaire consists of 4 questions scored from 0 to 100, that assesses the participants feeling of the TSST-A task. Higher scores indicate higher feelings of difficulty and stress.
Time frame: Day 1 and Day 29
Modified Drug Effects Questionnaire (DEQ)
To assess the effect of TP on subjective drug effects compared to placebo. This non-validated questionnaire consists of 4 questions scored from 0 to 100, that assesses the participants subjective experience after consuming the TP.
Time frame: Day 1 and Day 29, post-dose at 55, 85, 95, 110, 120, 150 minutes
Overall Well Being, Health, and Pain
To assess the effect of TP on overall well-being, health, and pain compared to placebo. This non-validated questionnaire consists of 4 questions scored from 0 to 100, that assesses overall quality of life with questions specifically on physical health and pain. Higher scores indicate better overall well-being, health, and pain.
Time frame: Day 1 to Days 15, 29, 36
Product Reliance Scale
To assess the effect of TP on the severity of dependence compared to placebo. A non-validated questionnaire consisting of 3 questions assessing how dependent participants feel when taking TP. Questions are scored on a 5-point Likert scale, ranging from 0 ("Never") to 4 ("Very Often"). Higher scores indicate higher feelings of dependence.
Time frame: Days 29, 31, 36
EMA Mood Assessments
To assess the effect of TP on mood compared to placebo. A non-validated questionnaire consisting of 13 questions assessing the participants emotional and mental/physical states they are feeling "right now." This questionnaire uses bipolar visual analogue scales in which participants how they feel "right now" on lines between two opposite feelings or physical sensations.
Time frame: Days 4, 8, 12, 16, 20, 24, 28, 30, 32, 34
Study Product Perception & Attitude Survey
To assess the effect of TP on study product perceptions and attitudes compared to placebo. A non-validated questionnaire consisting of multiple items assessing participants' subjective experiences with the study product, including effects on daily functioning, energy, sleep, mood, stress/anxiety, focus, pain, muscle recovery, tolerability, and product quality. Items are scored on a 5-point Likert scale ranging from "Strongly Disagree" to "Strongly Agree." Higher scores indicate more favorable perceptions of the study product (except for the side-effects item, where higher scores indicate greater perceived side effects).
Time frame: Days 15 and 29
Appraisal of Effects Survey
To assess participant-reported perceptions of the effects of the study product compared to placebo. A non-validated, self-administered questionnaire consisting of multiple items assessing participants' subjective experiences with the study product, including overall effect on how they feel, liking of the product, pain, muscle fatigue, mental focus/concentration, and calmness/stress. Items are scored using a 100-point visual analogue scale ranging from "Not at all" (0) to "Extremely" (100). Higher scores indicate greater perceived effects of the study product.
Time frame: Days 2, 6, 10, 14, 18, 22, and 26.
Safety Assessment - Incidence of Treatment-Emergent Adverse Events
Number and percentage of participants experiencing treatment-emergent adverse events from first dose through follow-up.
Time frame: Screening through Day 36 and follow-up phone call (approximately 8 weeks)
Safety Assessment - Vital Signs (Heart Rate)
Change in Heart Rate (beats per minute) from baseline to each study visit.
Time frame: Screening through Day 36
Safety Assessment - Vital Signs (Blood Pressure)
Change in Blood Pressure (mmHg) from baseline to each study visit.
Time frame: Screening through Day 36
Safety Assessment - Vital Signs (Respiratory Rate)
Change in Respiratory Rate (breaths per minute) from baseline to each study visit.
Time frame: Screening through Day 36
Safety Assessment - Vital Signs (Oxygen Saturation)
Change in Oxygen Saturation (SpO₂ %) from baseline to each study visit.
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Hematology - Hemoglobin)
To assess the safety of TP through the change from baseline to each study visit in hemoglobin (g/L).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Hematology - Hematocrit)
To assess the safety of TP through the change from baseline to each study visit in hematocrit (%).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Hematology - Red Blood Cell Count)
To assess the safety of TP through the change from baseline to each study visit in red blood cell count (×10E\^12/L).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Hematology - Red Cell Distribution Width)
To assess the safety of TP through the change from baseline to each study visit in red cell distribution width.
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Hematology - Mean Corpuscular Volume)
To assess the safety of TP through the change from baseline to each study visit in mean corpuscular volume (fL).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Hematology - Mean Corpuscular Hemoglobin)
To assess the safety of TP through the change from baseline to each study visit in mean corpuscular hemoglobin (pg).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Hematology - Mean Corpuscular Hemoglobin Concentration)
To assess the safety of TP through the change from baseline to each study visit in mean corpuscular hemoglobin concentration (g/L).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Hematology - White Blood Cell Count)
To assess the safety of TP through the change from baseline to each study visit in white blood cell count (×10\^9/L).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Hematology - Neutrophil Count)
To assess the safety of TP through the change from baseline to each study visit in Neutrophil Count (×10\^9/L).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Hematology - Eosinophil Count)
To assess the safety of TP through the change from baseline to each study visit in eosinophil count (×10\^9/L).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Hematology - Basophil Count)
To assess the safety of TP through the change from baseline to each study visit in basophil count (x 10\^9/L).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Hematology - Lymphocyte Count)
To assess the safety of TP through the change from baseline to each study visit in lymphocyte count (×10\^9/L).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Hematology - Monocyte Count)
To assess the safety of TP through the change from baseline to each study visit in hemoglobin (×10\^9/L).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Hematology - Platelet Count)
To assess the safety of TP through the change from baseline to each study visit in platelet count (×10\^9/µL).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Hematology - Mean Platelet Volume)
To assess the safety of TP through the change from baseline to each study visit in mean platelet volume (fL).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Hematology - Blood Smear Findings)
To assess the safety of TP through the change from baseline to each study visit in blood smear findings.
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Blood Urea Nitrogen)
To assess the safety of TP through the change from baseline to each study visit in blood urea nitrogen (mmol/L).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Creatinine)
To assess the safety of TP through the change from baseline to each study visit in creatinine (umol/L).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Estimated Glomerular Filtration Rate)
To assess the safety of TP through the change from baseline to each study visit in estimated glomerular filtration rate (ml/min/1.7m\^2).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Albumin)
To assess the safety of TP through the change from baseline to each study visit in albumin (g/L).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Random Glucose)
To assess the safety of TP through the change from baseline to each study visit in random glucose (mmol/L).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Fasting Glucose)
To assess the safety of TP through the change from baseline to each study visit in fasting glucose (mmol/L).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Total Protein)
To assess the safety of TP through the change from baseline to each study visit in total protein (g/L).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Sodium)
To assess the safety of TP through the change from baseline to each study visit in Sodium (mmol/L).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Potassium)
To assess the safety of TP through the change from baseline to each study visit in Potassium (mmol/L).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Clinical Chemistry - Chloride)
To assess the safety of TP through the change from baseline to each study visit in Chloride (mmol/L).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Liver Function Test - Aspartate Transaminase)
To assess the safety of TP through the change from baseline to each study visit in Aspartate Transaminase (AST) in U/L.
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Liver Function Test - Alanine Transaminase)
To assess the safety of TP through the change from baseline to each study visit in Alanine Transaminase (ALT) in U/L.
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Liver Function Test - Gamma-Glutamyl Transferase)
To assess the safety of TP through the change from baseline to each study visit in Gamma-Glutamyl Transferase (GGT) in U/L.
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Liver Function Test - Total Bilirubin)
To assess the safety of TP through the change from baseline to each study visit in Total Bilirubin in µmol/L.
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Liver Function Test - Direct Bilirubin)
To assess the safety of TP through the change from baseline to each study visit in Direct Bilirubin in µmol/L.
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Liver Function Test - Total Bile Acids)
To assess the safety of TP through the change from baseline to each study visit in Total Bile Acids in µmol/L.
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Liver Function Test - Alkaline Phosphatase)
To assess the safety of TP through the change from baseline to each study visit in Alkaline Phosphatase (ALP) in U/L.
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Liver Function Test - Prothrombin Time)
To assess the safety of TP through the change from baseline to each study visit in Prothrombin Time (PT) in seconds.
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Liver Function Test - International Normalized Ratio)
To assess the safety of TP through the change from baseline to each study visit in International Normalized Ratio (INR).
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Thyroid Function Test - Thyroid-Stimulating Hormone)
To assess the safety of TP through the change from baseline to each study visit in Thyroid-Stimulating Hormone (TSH) in mIU/L.
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Thyroid Function Test - Triiodothyronine)
To assess the safety of TP through the change from baseline to each study visit in Triiodothyronine (T3) in nmol/L.
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Thyroid Function Test - Thyroxine )
To assess the safety of TP through the change from baseline to each study visit in Thyroxine (T4) in ug/dL.
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Lipid Panel - Total Cholesterol)
To assess the safety of TP through the change from baseline to each study visit in Total Cholesterol in mmol/L.
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Lipid Panel - HDL)
To assess the safety of TP through the change from baseline to each study visit in high-density lipoprotein (HDL) cholesterol in mmol/L.
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Lipid Panel - LDL)
To assess the safety of TP through the change from baseline to each study visit in low-density lipoprotein (LDL) cholesterol in mmol/L.
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Lipid Panel - HDL:LDL Ratio)
To assess the safety of TP through the change from baseline to each study visit in HDL:LDL Ratio.
Time frame: Screening through Day 36
Safety Assessment - Clinical Laboratory Test (Lipid Panel - Triglycerides)
To assess the safety of TP through the change from baseline to each study visit in Triglycerides in mmol/L.
Time frame: Screening through Day 36
Safety Assessment: Change in Subjective Opiate Withdrawal Scale (SOWS)
To test the safety of TP by assessing the change in SOWS. This validated questionnaire is used to assess participants intensity of potential opioid withdrawal symptoms. Items are scored on a 5-point Likert scale ranging from 0 ('Not at all') to 4 ('Extremely'). Higher scores indicate higher potential withdrawal symptoms.
Time frame: Day 1, Day 29, and follow-up visits (Day 31 and Day 36)
Safety Assessment: Change in Clinical Opiate Withdrawal Scale (COWS)
To test the safety of TP by assessing the change in COWS. This validated questionnaire is used to assess common signs and symptoms of opiate withdrawal. Items are scored from 0 to 48. Higher scores indicate higher withdrawal symptoms.
Time frame: Day 29, and follow-up visits (Day 31 and Day 36)
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Jan 2027, 9 months after the start.
Of 105 industry-sponsored interventional studies with no phase under Anxiety Disorders, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 16. This study's planned 9 months is above that.
Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Sep 2026 → Jan 2027 and completion Oct 2026 → Jan 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Botanic Tonics, LLC